LUC00132I2 - - Google Patents
Download PDFInfo
- Publication number
- LUC00132I2 LUC00132I2 LU00132C LUC00132C LUC00132I2 LU C00132 I2 LUC00132 I2 LU C00132I2 LU 00132 C LU00132 C LU 00132C LU C00132 C LUC00132 C LU C00132C LU C00132 I2 LUC00132 I2 LU C00132I2
- Authority
- LU
- Luxembourg
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Obesity (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41015810P | 2010-11-04 | 2010-11-04 | |
US41195310P | 2010-11-10 | 2010-11-10 | |
US41259410P | 2010-11-11 | 2010-11-11 | |
US201161448785P | 2011-03-03 | 2011-03-03 | |
PCT/US2011/058869 WO2012061448A1 (fr) | 2010-11-04 | 2011-11-02 | Anticorps anti-il-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
LUC00132I1 LUC00132I1 (fr) | 2019-10-16 |
LUC00132I2 true LUC00132I2 (fr) | 2020-07-16 |
Family
ID=44936573
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU00132C LUC00132I2 (fr) | 2010-11-04 | 2019-10-14 |
Country Status (39)
Country | Link |
---|---|
US (5) | US8778346B2 (fr) |
EP (4) | EP2635601B1 (fr) |
JP (3) | JP6126532B2 (fr) |
KR (2) | KR101931591B1 (fr) |
CN (2) | CN103282382B (fr) |
AP (1) | AP3953A (fr) |
AR (1) | AR083747A1 (fr) |
AU (3) | AU2011323426B2 (fr) |
BR (1) | BR112013011065B1 (fr) |
CA (2) | CA3017116A1 (fr) |
CO (1) | CO6801628A2 (fr) |
CY (2) | CY1118014T1 (fr) |
DK (1) | DK2635601T3 (fr) |
EA (2) | EA030436B1 (fr) |
EC (1) | ECSP13012649A (fr) |
ES (1) | ES2593754T3 (fr) |
GE (1) | GEP201706733B (fr) |
HK (1) | HK1247940A1 (fr) |
HR (1) | HRP20161141T1 (fr) |
HU (2) | HUE030916T2 (fr) |
IL (2) | IL225648A (fr) |
LT (2) | LT2635601T (fr) |
LU (1) | LUC00132I2 (fr) |
MA (1) | MA34641B1 (fr) |
ME (1) | ME02499B (fr) |
MX (3) | MX343858B (fr) |
MY (1) | MY162791A (fr) |
NL (1) | NL301013I2 (fr) |
NO (1) | NO2019038I1 (fr) |
NZ (1) | NZ610592A (fr) |
PE (1) | PE20141162A1 (fr) |
PL (1) | PL2635601T3 (fr) |
PT (1) | PT2635601T (fr) |
RS (1) | RS55161B1 (fr) |
SG (2) | SG10201604605VA (fr) |
SI (1) | SI2635601T1 (fr) |
TW (2) | TWI545133B (fr) |
UY (1) | UY33703A (fr) |
WO (1) | WO2012061448A1 (fr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
EP2635601B1 (fr) | 2010-11-04 | 2016-07-20 | Boehringer Ingelheim International GmbH | Anticorps anti-il-23 |
PL3326649T3 (pl) * | 2012-05-03 | 2022-04-25 | Boehringer Ingelheim International Gmbh | Przeciwciała anty-il-23p19 |
TWI636063B (zh) * | 2013-03-08 | 2018-09-21 | 美國禮來大藥廠 | 結合il-23之抗體 |
US20160060337A1 (en) | 2013-03-15 | 2016-03-03 | Amgen Inc. | Methods for treating psoriasis using an anti-il-23 antibody |
CA2906384A1 (fr) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Methodes de traitement de la maladie de crohn a l'aide d'un anticorps anti-il-23 |
JP2017524359A (ja) * | 2014-07-24 | 2017-08-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Il−23a関連疾患の処置に有用なバイオマーカー |
SG11201701423RA (en) * | 2014-09-03 | 2017-03-30 | Boehringer Ingelheim Int | Compound targeting il-23a and tnf-alpha and uses thereof |
EP3253794A1 (fr) * | 2015-02-04 | 2017-12-13 | Boehringer Ingelheim International GmbH | Méthodes de traitement de maladies inflammatoires |
EA201792282A1 (ru) | 2015-04-14 | 2018-04-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Способы лечения заболеваний |
JP6866345B2 (ja) | 2015-07-23 | 2021-04-28 | ベーリンガー・インゲルハイム・インターナショナル・ゲーエムベーハー | Il−23a及びb細胞活性化因子(baff)を標的とする化合物及びその使用 |
JP6909208B2 (ja) | 2015-09-17 | 2021-07-28 | アムジェン インコーポレイテッド | Il23経路バイオマーカーを使用するil23アンタゴニストに対する臨床応答の予測 |
TWI733695B (zh) * | 2015-09-18 | 2021-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
KR20180069070A (ko) | 2015-11-03 | 2018-06-22 | 얀센 바이오테크 인코포레이티드 | Tim-3과 특이적으로 결합하는 항체 및 그의 용도 |
JP2019508370A (ja) | 2015-12-22 | 2019-03-28 | アムジェン インコーポレイテッド | Il23アンタゴニストに対する臨床応答の予測因子としてのccl20 |
AU2017250583A1 (en) | 2016-04-15 | 2018-08-16 | Boehringer Ingelheim International Gmbh | Methods of treating inflammatory diseases |
WO2018071504A2 (fr) | 2016-10-14 | 2018-04-19 | Boehringer Ingelheim International Gmbh | Méthodes de traitement de maladies |
MX2020008258A (es) * | 2018-02-05 | 2020-11-13 | Tesaro Inc | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. |
TWI837532B (zh) * | 2018-03-30 | 2024-04-01 | 美商美國禮來大藥廠 | 治療潰瘍性結腸炎之方法 |
US20210277105A1 (en) | 2018-07-13 | 2021-09-09 | Astrazeneca Collaboration Ventures, Llc | Treating ulcerative colitis with brazikumab |
CN110818793A (zh) * | 2018-08-14 | 2020-02-21 | 中山康方生物医药有限公司 | 抗IL-1β的抗体、其药物组合物及其用途 |
CN109810947B (zh) * | 2019-01-18 | 2021-06-11 | 北京贝来生物科技有限公司 | 一种抑制Th17细胞活化的间充质干细胞及其制备方法和应用 |
CN113825768A (zh) * | 2019-04-15 | 2021-12-21 | 太阳药业有限公司 | 用于治疗患有银屑病关节炎的受试者的方法 |
CA3164996A1 (fr) | 2019-12-20 | 2021-06-14 | Novarock Biotherapeutics, Ltd. | Anticorps anti-interleukine-23 p19 et leurs methodes d'utilisation |
CN111956606B (zh) * | 2020-08-31 | 2021-05-14 | 江苏荃信生物医药有限公司 | 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂 |
TW202224702A (zh) | 2020-09-10 | 2022-07-01 | 美商美國禮來大藥廠 | 治療性抗體調配物 |
EP4228693A1 (fr) * | 2020-10-13 | 2023-08-23 | Janssen Biotech, Inc. | Immunité à médiation par des lymphocytes t biologiquement modifiés, matériaux et autres procédés pour la modulation d'un ensemble de différenciation iv &/ou viii |
CA3219846A1 (fr) | 2021-05-28 | 2022-12-01 | Venkatesh Krishnan | Regulation d'anticorps anti-il-23p19 de genes impliques dans la rectocolite hemorragique |
KR20230009815A (ko) | 2021-07-09 | 2023-01-17 | 연세대학교 산학협력단 | Il-23에 의해 매개되는 질환의 중증도 예측용 조성물 |
WO2023056417A1 (fr) | 2021-09-30 | 2023-04-06 | Eli Lilly And Company | Régulation d'anticorps anti-il-23p19 de gènes impliqués dans l'urgence intestinale dans la colite ulcéreuse |
WO2024077113A1 (fr) | 2022-10-06 | 2024-04-11 | Eli Lilly And Company | Méthodes de traitement de la fatigue liée à la colite ulcéreuse |
KR20240058012A (ko) | 2022-10-21 | 2024-05-03 | 주식회사 종근당 | 안정한 항체 조성물 |
CN117875575B (zh) * | 2024-03-12 | 2024-05-28 | 中国电子科技集团公司第二十九研究所 | 一种基于混合仿生算法的干扰资源分配方法 |
Family Cites Families (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
WO1981001145A1 (fr) | 1979-10-18 | 1981-04-30 | Univ Illinois | Medicaments "pro-drugs" pouvant etre actives par des enzymes hydrolytiques |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
EP0206448B1 (fr) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hémoglobine liée à un poly(oxyde d'alkylène) |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
EP0402226A1 (fr) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Vecteurs de transformation de la levure yarrowia |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
CA2103059C (fr) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Methode de production d'anticorps humanises |
WO1994004188A1 (fr) | 1992-08-21 | 1994-03-03 | Genentech, Inc. | Procede pour traiter une affection ayant pour origine l'antigene 1 associe a la fonction lymphocytaire |
NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
PE20000183A1 (es) | 1997-07-25 | 2000-03-11 | Schering Corp | Citoquinas de mamiferos y reactivos relacionados |
US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
AU2661199A (en) | 1998-02-06 | 1999-08-23 | Schering Corporation | Mammalian receptor proteins; related reagents and methods |
ATE474849T1 (de) | 1998-04-14 | 2010-08-15 | Chugai Pharmaceutical Co Ltd | Neues cytokinartiges protein |
US7090847B1 (en) | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
HU230679B1 (en) | 1999-09-09 | 2017-08-28 | Merck Sharp & Dohme | Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions |
ES2307618T3 (es) | 2000-05-10 | 2008-12-01 | Schering Corporation | Proteinas subunidades de receptores de cotocinas de mamiferos, reactivos y metodos relacionados. |
US7422743B2 (en) | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
EP1449431A4 (fr) | 2001-10-24 | 2007-11-28 | Chugai Pharmaceutical Co Ltd | Animal non humain a srgf genetiquement modifie |
KR100913714B1 (ko) | 2001-11-08 | 2009-08-24 | 패시트 바이오테크 코포레이션 | Igg 항체의 안정한 액상 약학 제형물 |
KR101053412B1 (ko) | 2002-10-30 | 2011-08-01 | 제넨테크, 인크. | Il―17 생성의 억제 |
EP1587834B1 (fr) | 2002-12-23 | 2011-07-06 | Schering Corporation | Utilisations de la cytokine il-23 de mammiferes et reactifs correspondants |
WO2004071517A2 (fr) | 2003-02-06 | 2004-08-26 | Schering Corporation | Utilisations de cytokine de mammifere; reactifs associes |
US7282204B2 (en) | 2003-03-10 | 2007-10-16 | Schering Corporation | Uses of IL-23 agonists and antagonists; related reagents |
US7413894B2 (en) | 2003-07-01 | 2008-08-19 | University Of Virginia Patent Foundation | TAG-1 and TAG-2 proteins and uses thereof |
WO2005044855A2 (fr) | 2003-11-04 | 2005-05-19 | Chiron Corporation | Utilisation d'anticorps monoclonaux antagonistes anti-cd40 pour le traitement de myelome multiple |
US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
PT1682178E (pt) | 2003-11-04 | 2010-10-21 | Novartis Vaccines & Diagnostic | Métodos de terapêutica para cancros que expressam o antigénio cd40 |
US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
EP1901768B1 (fr) | 2004-02-17 | 2011-11-16 | Schering Corporation | Procedes de modulation de l'activite de il-23; reactifs correspondants |
US20050287593A1 (en) | 2004-05-03 | 2005-12-29 | Schering Corporation | Use of cytokine expression to predict skin inflammation; methods of treatment |
BRPI0510617A (pt) | 2004-05-03 | 2007-10-30 | Schering Corp | uso de expressão de il-17 para prever inflamação de pele; processos de tratamento |
AU2005289594B2 (en) | 2004-09-27 | 2012-02-02 | Centocor, Inc. | Srage mimetibody, compositions, methods and uses |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP1853707A2 (fr) | 2004-12-20 | 2007-11-14 | Schering Corporation | Utilisations d'antagonistes il-23 dans le traitement du diabete mellitus |
AU2006265898A1 (en) | 2005-06-30 | 2007-01-11 | Archemix Corp. | Polynucleotides and polypeptides of the IL-12 family of cytokines |
HUE042561T2 (hu) | 2005-06-30 | 2019-07-29 | Janssen Biotech Inc | Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások |
CN101248088A (zh) * | 2005-08-25 | 2008-08-20 | 伊莱利利公司 | 抗il-23抗体 |
DK1937721T3 (da) * | 2005-08-25 | 2010-10-18 | Lilly Co Eli | Anti-IL-23 antistoffer |
SG165322A1 (en) | 2005-08-31 | 2010-10-28 | Schering Corp | Engineered anti-il-23 antibodies |
EP1933869B1 (fr) | 2005-09-01 | 2009-10-14 | Schering Corporation | Utilisation d'antagonistes de l'il-23 et de l'il-17 pour le traitement de la maladie inflammatoire oculaire auto-immune |
BRPI0620914A2 (pt) | 2005-12-28 | 2011-11-29 | Centocor Inc | marcadores e métodos para avaliar e tratar psorìase e distúrbios relacionados |
ES2517420T3 (es) | 2005-12-29 | 2014-11-03 | Janssen Biotech, Inc. | Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos |
US7790862B2 (en) | 2006-06-13 | 2010-09-07 | Zymogenetics, Inc. | IL-17 and IL-23 antagonists and methods of using the same |
US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
US20080311043A1 (en) | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
WO2007149814A1 (fr) | 2006-06-19 | 2007-12-27 | Wyeth | Procédés de modulation de l'il-22 et de l'il-17 |
CN101600457B (zh) | 2007-01-09 | 2014-01-08 | 惠氏公司 | 抗il-13抗体调配物和其用途 |
TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Il-23拮抗劑於治療感染之用途 |
MX2009008769A (es) | 2007-02-16 | 2009-08-25 | Wyeth Corp | Formulaciones de proteina que contienen sorbitol. |
KR101520110B1 (ko) | 2007-02-23 | 2015-05-18 | 머크 샤프 앤드 돔 코포레이션 | 가공된 항-IL-23p19 항체 |
CN101663320A (zh) * | 2007-02-23 | 2010-03-03 | 先灵公司 | 工程改造的抗IL-23p19抗体 |
EP2417974A1 (fr) | 2007-02-28 | 2012-02-15 | Schering Corporation | Polythérapie pour le traitement de maladies immunes |
WO2009032954A1 (fr) | 2007-09-04 | 2009-03-12 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Délétions dans le domaine ii de l'exotoxine a de pseudomonas qui réduisent la toxicité non spécifique |
AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
EP2212442A1 (fr) | 2007-10-26 | 2010-08-04 | Galderma Research & Development | Procédé non invasif pour études pharmaco-génomiques de maladies inflammatoires cutanées et leur procédé de diagnostic |
CA2607771A1 (fr) | 2007-11-01 | 2009-05-01 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence | Anticorps recombinant humanise contre le virus de l'encephalite equine du venezuela |
NZ602498A (en) | 2007-11-30 | 2014-08-29 | Abbvie Inc | Protein formulations and methods of making same |
WO2009082624A2 (fr) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonistes de il-17a, il-17f et il-23 et procédés d'utilisation de ceux-ci |
KR20160116056A (ko) | 2008-08-14 | 2016-10-06 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | 항-il-12/il-23 항체 |
US8263748B2 (en) | 2008-08-27 | 2012-09-11 | Schering Corporation | Lyophilized formulations of engineered anti-IL-23p19 antibodies |
US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
CA2757237A1 (fr) | 2009-04-01 | 2010-10-14 | Jane Elizabeth Clarkson | Immunoglobulines anti-il-23 |
WO2010115092A2 (fr) | 2009-04-02 | 2010-10-07 | The Johns Hopkins University | Compositions et procédés pour le traitement ou la prévention des maladies intestinales inflammatoires chroniques et du cancer du colon |
EP2456787A4 (fr) | 2009-07-24 | 2013-01-30 | Univ Leland Stanford Junior | Compositions de cytokine et leurs méthodes d utilisation |
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
EP2504031A4 (fr) | 2009-11-24 | 2013-06-26 | Alderbio Holdings Llc | Anticorps anti-il-6 et leur utilisation |
US8257397B2 (en) | 2009-12-02 | 2012-09-04 | Spartek Medical, Inc. | Low profile spinal prosthesis incorporating a bone anchor having a deflectable post and a compound spinal rod |
GB201013975D0 (en) | 2010-08-20 | 2010-10-06 | Imp Innovations Ltd | Method of treating desease |
AU2011218243A1 (en) | 2010-02-18 | 2012-10-04 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind IL-23 |
CA2789061A1 (fr) | 2010-02-26 | 2011-09-01 | Henrik Parshad | Compositions stables contenant des anticorps |
CN102946861B (zh) | 2010-03-01 | 2016-01-20 | 西托戴恩有限公司 | 浓缩蛋白制剂及其用途 |
EP2583098B1 (fr) | 2010-06-15 | 2018-08-08 | Celgene Corporation | Biomarqueurs pour le traitement du psoriasis |
US20110311527A1 (en) | 2010-06-16 | 2011-12-22 | Allergan, Inc. | IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS |
MX341309B (es) | 2010-07-20 | 2016-08-12 | Cephalon Australia Pty Ltd | Anticuerpos especificos del heterodimero de anti-il-23. |
CN103261222B (zh) | 2010-09-10 | 2017-07-28 | 医疗免疫有限公司 | 抗体衍生物 |
EP2635601B1 (fr) | 2010-11-04 | 2016-07-20 | Boehringer Ingelheim International GmbH | Anticorps anti-il-23 |
GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
TW201309330A (zh) | 2011-01-28 | 2013-03-01 | Abbott Lab | 包含糖基化抗體之組合物及其用途 |
US9078894B2 (en) | 2011-02-04 | 2015-07-14 | Ab Science | Treatment of severe persistant asthma with masitinib |
PL3326649T3 (pl) | 2012-05-03 | 2022-04-25 | Boehringer Ingelheim International Gmbh | Przeciwciała anty-il-23p19 |
US9803010B2 (en) | 2012-06-27 | 2017-10-31 | Merck Sharp & Dohme Corp. | Crystalline anti-human IL-23p19 antibodies |
CA2906384A1 (fr) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Methodes de traitement de la maladie de crohn a l'aide d'un anticorps anti-il-23 |
US20160060337A1 (en) | 2013-03-15 | 2016-03-03 | Amgen Inc. | Methods for treating psoriasis using an anti-il-23 antibody |
KR20140119396A (ko) | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
SG11201701423RA (en) | 2014-09-03 | 2017-03-30 | Boehringer Ingelheim Int | Compound targeting il-23a and tnf-alpha and uses thereof |
EP3253794A1 (fr) | 2015-02-04 | 2017-12-13 | Boehringer Ingelheim International GmbH | Méthodes de traitement de maladies inflammatoires |
JP6866345B2 (ja) | 2015-07-23 | 2021-04-28 | ベーリンガー・インゲルハイム・インターナショナル・ゲーエムベーハー | Il−23a及びb細胞活性化因子(baff)を標的とする化合物及びその使用 |
TWI733695B (zh) | 2015-09-18 | 2021-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
-
2011
- 2011-11-02 EP EP11781949.0A patent/EP2635601B1/fr active Active
- 2011-11-02 AP AP2013006820A patent/AP3953A/en active
- 2011-11-02 PL PL11781949T patent/PL2635601T3/pl unknown
- 2011-11-02 SG SG10201604605VA patent/SG10201604605VA/en unknown
- 2011-11-02 RS RS20160762A patent/RS55161B1/sr unknown
- 2011-11-02 EP EP16178404.6A patent/EP3115375A1/fr not_active Withdrawn
- 2011-11-02 AU AU2011323426A patent/AU2011323426B2/en active Active
- 2011-11-02 JP JP2013537771A patent/JP6126532B2/ja active Active
- 2011-11-02 SG SG2013031745A patent/SG190006A1/en unknown
- 2011-11-02 DK DK11781949.0T patent/DK2635601T3/en active
- 2011-11-02 NZ NZ610592A patent/NZ610592A/en unknown
- 2011-11-02 HU HUE11781949A patent/HUE030916T2/en unknown
- 2011-11-02 CN CN201180064083.5A patent/CN103282382B/zh active Active
- 2011-11-02 US US13/287,208 patent/US8778346B2/en active Active
- 2011-11-02 MX MX2013005015A patent/MX343858B/es active IP Right Grant
- 2011-11-02 KR KR1020137011474A patent/KR101931591B1/ko active IP Right Grant
- 2011-11-02 EA EA201300530A patent/EA030436B1/ru active Protection Beyond IP Right Term
- 2011-11-02 BR BR112013011065-1A patent/BR112013011065B1/pt active IP Right Grant
- 2011-11-02 KR KR1020187036509A patent/KR102049223B1/ko active IP Right Grant
- 2011-11-02 PT PT117819490T patent/PT2635601T/pt unknown
- 2011-11-02 MX MX2016015419A patent/MX362039B/es unknown
- 2011-11-02 EP EP18188208.5A patent/EP3456740A1/fr not_active Withdrawn
- 2011-11-02 MX MX2019000046A patent/MX2019000046A/es unknown
- 2011-11-02 MY MYPI2013001519A patent/MY162791A/en unknown
- 2011-11-02 GE GEAP201113106A patent/GEP201706733B/en unknown
- 2011-11-02 SI SI201130958A patent/SI2635601T1/sl unknown
- 2011-11-02 EA EA201890548A patent/EA201890548A1/ru unknown
- 2011-11-02 LT LTEP11781949.0T patent/LT2635601T/lt unknown
- 2011-11-02 CN CN201710917166.3A patent/CN107522784B/zh active Active
- 2011-11-02 CA CA3017116A patent/CA3017116A1/fr not_active Abandoned
- 2011-11-02 EP EP17179739.2A patent/EP3281954A1/fr not_active Withdrawn
- 2011-11-02 ES ES11781949.0T patent/ES2593754T3/es active Active
- 2011-11-02 PE PE2013000951A patent/PE20141162A1/es active IP Right Grant
- 2011-11-02 CA CA2816950A patent/CA2816950C/fr active Active
- 2011-11-02 WO PCT/US2011/058869 patent/WO2012061448A1/fr active Application Filing
- 2011-11-03 TW TW100140204A patent/TWI545133B/zh active
- 2011-11-03 AR ARP110104094A patent/AR083747A1/es active IP Right Grant
- 2011-11-03 UY UY0001033703A patent/UY33703A/es active IP Right Grant
- 2011-11-03 TW TW105114183A patent/TWI653242B/zh active
-
2012
- 2012-11-02 ME MEP-2016-176A patent/ME02499B/fr unknown
-
2013
- 2013-04-09 IL IL225648A patent/IL225648A/en active Protection Beyond IP Right Term
- 2013-05-02 MA MA35866A patent/MA34641B1/fr unknown
- 2013-05-24 CO CO13128280A patent/CO6801628A2/es active IP Right Grant
- 2013-05-30 EC ECSP13012649 patent/ECSP13012649A/es unknown
- 2013-11-20 HK HK18107343.9A patent/HK1247940A1/zh unknown
-
2014
- 2014-06-12 US US14/302,986 patent/US9441036B2/en active Active
-
2016
- 2016-02-29 IL IL244335A patent/IL244335A/en active Protection Beyond IP Right Term
- 2016-08-04 US US15/228,254 patent/US10202448B2/en active Active
- 2016-09-06 HR HRP20161141TT patent/HRP20161141T1/hr unknown
- 2016-09-13 CY CY20161100899T patent/CY1118014T1/el unknown
- 2016-12-16 AU AU2016273970A patent/AU2016273970B2/en active Active
-
2017
- 2017-01-13 JP JP2017003955A patent/JP6445596B2/ja active Active
-
2018
- 2018-09-24 AU AU2018236692A patent/AU2018236692C1/en active Active
- 2018-11-29 JP JP2018223469A patent/JP6758361B2/ja active Active
-
2019
- 2019-01-25 US US16/257,463 patent/US20190144534A1/en not_active Abandoned
- 2019-10-14 HU HUS1900048 patent/HUS1900048I1/hu unknown
- 2019-10-14 LU LU00132C patent/LUC00132I2/fr unknown
- 2019-10-15 LT LTPA2019518C patent/LTC2635601I2/lt unknown
- 2019-10-16 NL NL301013C patent/NL301013I2/nl unknown
- 2019-10-17 NO NO2019038C patent/NO2019038I1/no unknown
- 2019-10-17 CY CY2019040C patent/CY2019040I1/el unknown
-
2020
- 2020-10-09 US US17/066,994 patent/US20210198355A1/en not_active Abandoned